P542: A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB)

• Mika Kontro,
• Timo Siitonen,
• Johanna Rimpilainen,
• Marja Pyorala,
• Inka Pawlitzky,
• Sofia Aakko,
• Marie-Louise Fjaellskog,
• Maija Hollmén,
• Naval Daver

Affiliations

Mika Kontro

1 HUS, Hematology, Helsinki, Finland

Timo Siitonen

2 Oulu University Hospital, Hematology, Oulu, Finland

Johanna Rimpilainen

3 Tampere University Hospital, Hematology, Tampere, Finland

Marja Pyorala

4 Kuopio University Hospital, Hematology, Kuopio, Finland

Inka Pawlitzky

5 Faron Pharmaceuticals, Turku, Finland

Sofia Aakko

5 Faron Pharmaceuticals, Turku, Finland

Marie-Louise Fjaellskog

5 Faron Pharmaceuticals, Turku, Finland

Maija Hollmén

5 Faron Pharmaceuticals, Turku, Finland

Naval Daver

6 MD Anderson Main Building, Houston, United States